Key Highlights

  • Net loss was USD 1.2 million, or USD 0.31 per share, versus USD 0.91 estimated.
  • Research and development expense fell to USD 225 thousand from USD 688 thousand.
  • General and administrative expense fell to USD 1.0 million from USD 2.0 million.
  • Cash and equivalents were USD 3.1 million at September 30, 2026.

Loss Narrows on Lower Spending

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) reported a third-quarter net loss and comprehensive loss of USD 1,246,871 versus USD 2,685,705, or USD 0.31 per share versus USD 1.31, against an estimated loss of USD 0.91 per share. Total operating expenses fell to USD 1,265,311 from USD 2,733,803.

General and administrative expenses were USD 1,040,335 versus USD 2,044,937, Research and Development expenses were USD 224,576 versus USD 688,465, and interest and Dividend income was USD 18,440 versus USD 48,098.

The statement of stockholders' Equity shows equity-based compensation of USD 108,427 for Options and issuance costs of USD 22,717 related to Warrant inducements during the nine months, and a balance at June 30, 2026 of USD 4,091,708 in total stockholders' equity.

Total stockholders' equity was USD 2,904,917 at September 30, 2026 versus USD 2,738,726 at December 31, 2025, with an accumulated Deficit of USD 46,026,121. The equity statement lists warrant inducement proceeds, net of issuance costs, of USD 2,208,890 and warrant issuance proceeds of USD 2,607,618.

Nine-Month Results

For the nine months, net loss was USD 7,065,976 versus USD 10,198,372, or USD 2.26 per share versus USD 5.23. General and administrative expenses were USD 5,417,396 versus USD 6,955,907, research and development was USD 1,701,235 versus USD 3,433,845 and total operating expenses were USD 7,120,090 versus USD 10,396,071. Interest and dividend income was USD 54,114 versus USD 197,699.

Depreciation expense was USD 400 for the quarter and USD 1,459 for the nine months versus USD 6,319, a small line that shows how little of the cost base is fixed assets.

Pipeline and Balance Sheet

The company describes itself as a "late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions", with a pipeline anchored by four Assets that include CAD-1005, a first-in-class 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia.

Cash and cash equivalents were USD 3.1 million at September 30, 2026. The filing says the company believes it regained compliance with the Nasdaq stockholders' equity requirement after receiving net proceeds from financing, and it also states that its factors raise substantial doubt about its ability to continue as a Going Concern for one year after the financial statements are issued.

The Balance Sheet shows total assets of USD 3,456,253 versus USD 4,326,708 at December 31, 2025, and total liabilities of USD 551,336 versus USD 1,587,982, with accrued liabilities falling to USD 82,516 from USD 937,319. Net cash used in Operating Activities for the nine months was USD 7,150,976 versus USD 10,031,707.

Items to Follow

Reference points include research spending as the lead program advances, the cash balance against quarterly operating expenses near USD 1.3 million, warrant inducement activity and continued compliance with exchange equity standards.